Preview Mode Links will not work in preview mode

Oct 8, 2019

Recently there has been some attempt to amalgamate platform technologies within start-up and earlystage drug discovery and development companies to increase drug candidate pipeline numbers. This strategy does not come without risks, but has quietly been implemented by a number of platform-drug discovery and development (PD3) companies.

This episode, part 2 explores this issue and use Moderna Therapeutics as our case study to highlight the limitations and potential impact on company valuation of such an integrated approach.

Original article by Dr Urban A. Kiernan and Dr Stephen Naylor

If you'd like to view the original article then follow the link below:

You can also download the original article pdf here:

For more information on Drug Discovery World, head to: